Fermenta Biotech Limited share price

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

• Fermenta Biotech Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,393 crore.
• It trades at 23.5 times its last 12 months' earnings and 3.4 times book value.
• Revenue grew 14.5% a year over the last 3 years.
• Return on equity was 18.7% and return on capital employed 24.2% in the latest year.
• Debt was 0.28 times shareholders' equity.
• The share price is 16.6% below its 52-week high.
• Promoters and insiders hold about 65.9%; institutions about 0.0%.

Fermenta Biotech Limited, together with its subsidiaries, engages in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products in India, Europe, the United States, and internationally. It operates through Chemicals/Bulk Drug and Property segments. The company offers vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for injectables, soft gel capsules, premixes, food and beverage fortification applications; and vitamin K1, vitamin E50, phenyramidol and silicon dioxide, and fish oil cholesterol. It also provides fortified rice kernel; and Fermase PS 250 and penicillin G acylase used in manufacturing processes of various antibiotics. In addition, the company offers design, engineering, procurement, and construction of wastewater treatment plants, STPs, and ETPs, as well as…

Employees

630

Head office

Thane

HealthcareDrug Manufacturers - Specialty & Generic

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Consolidated figures in ₹ crore / View Standalone

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Consolidated figures in ₹ crore, as at 31 March

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Consolidated figures in ₹ crore, financial years ending March

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Filings made by the company with NSE; documents open on NSE's website.

Ex-dividend date

5 Aug 2026

Latest quarter

30 Jun 2026

Financial year end

31 Mar 2026

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.